Belzutifan: a novel therapy for von Hippel-Lindau disease

Jingcheng Zhou^{1

2}, Kan Gong^{3

4}

Affiliations

¹ Department of Urology, Peking University First Hospital, Beijing, China.
² Institute of Urology, Peking University, Beijing, China.
³ Department of Urology, Peking University First Hospital, Beijing, China. gongkan_pku@126.com.
⁴ Institute of Urology, Peking University, Beijing, China. gongkan_pku@126.com.

Comment

Jingcheng Zhou et al. Nat Rev Nephrol. 2022 Apr.

. 2022 Apr;18(4):205-206.

doi: 10.1038/s41581-022-00544-5.

Jingcheng Zhou^{1

2}, Kan Gong^{3

4}

¹ Department of Urology, Peking University First Hospital, Beijing, China.
² Institute of Urology, Peking University, Beijing, China.
³ Department of Urology, Peking University First Hospital, Beijing, China. gongkan_pku@126.com.
⁴ Institute of Urology, Peking University, Beijing, China. gongkan_pku@126.com.

No abstract available

Comment on

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Jonasch E, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. N Engl J Med. 2021. PMID: 34818478 Free PMC article. Clinical Trial.

1. Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706–720 (2019). - DOI
1. Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N. Engl. J. Med. 385, 2036–2046 (2021). - DOI
1. Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682 (2002). - DOI
1. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994). - DOI
1. Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL–ElonginC–ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455–461 (1999). - DOI